Andre Terzic, M.D., Ph.D.
Scientific and Strategy ExpertA pioneer in cardiovascular regenerative medicine, Dr. Terzic has dedicated his career to next-generation diagnostic and therapeutic solutions, including first-in-class biologics for heart failure. An innovator with 96 patents across 17 technologies, his research includes over 450 articles cited 18,000 times. Dr. Terzic brings a wealth of scientific and strategy expertise in the regenerative medicine space to help guide H-CYTE’s vision.
Dr. Terzic is Chair, FDA Pharmaceutical Science & Clinical Pharmacology Advisory Committee; served as President, American Society for Clinical Pharmacology & Therapeutics and contributed to the advisory boards of the Swiss Institute for Regenerative Medicine; Science Foundation Ireland; Spanish Net of Cellular Therapy; Centro Cardiologico Monzino and Berlin Institute of Health. He is Co-Founder of Rion LLC.
Dr. Terzic received the American Heart Association Prize “for pioneering emerging technologies to advance diagnosis and treatment of cardiovascular disorders,” the Madrid Award for Excellence in Regenerative Research “for leadership and success in translating stem cell theory into practice,” and numerous other recognitions including the Martin Rehfuss Medal in Medicine and the Henry Elliott Distinguished Service Award from the American Society for Clinical Pharmacology & Therapeutics.
Dr. Terzic trained at University of Paris, Belgrade, and University of Illinois followed by fellowships at the French National Institutes of Health, Thomas Jefferson University and Mayo Clinic. A veteran of Mayo Clinic, including serving as former Associate Dean for Research, he currently serves as Director, Center for Regenerative Medicine; Professor of Medicine and Pharmacology; Chair, President’s Discovery-Translation Advisory Group and Director, National Institutes of Health “Cardiovasology” Program.